A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 2-Parallel Group, Phase III Study to Compare Efficacy and Safety of Masitinib 9 mg/kg/Day in Combination With Gemcitabine Compared to Placebo in Combination With Gemcitabine in Treatment of Patients With Advanced/Metastatic Pancreatic Cancer.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 09 Apr 2015
At a glance
- Drugs Masitinib (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Registrational; Therapeutic Use
- Sponsors AB Science
- 07 Jun 2017 Biomarkers information updated
- 09 Apr 2015 According to AB Science media release, results published in the journal Annals of Oncology.
- 09 Apr 2015 Results (Subgroup analysis) published in the AB Science Media Release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History